Retraction
QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin
Paper Information
Record ID:
51246
Author(s):
Publication Date:
September 16, 2016
Retraction Date:
January 23, 2024
(1.8 year years ago)
Subjects:
Specific Fields:
Biochemistry Biology - Cellular Biology - Molecular Toxicology Medicine - Alternative
Biochemistry Biology - Cellular Biology - Molecular Toxicology Medicine - Alternative
Institutions:
Country:
🇨🇳 ChinaArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1371/journal.pone.0297842Additional Notes:
see also: https://pubpeer.com/publications/63091FDB5DBD440129DE207EDA04FD
Citations (10)
10
Total Citations1
Post-Retraction(10.0%)
8
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
0
Within 1 year
0
After 2+ years
371
Days since retraction (latest)
Phytopharmaceutical and innovative nanocarriers for chronic kidney diseases: a comprehensive review
M. Keerthana Devi, B. Sajeev Kumar
Discover Plants.
Open Access
Published: Jan 2025
371 days after retraction
Retraction: QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin
Zhanmei Zhou, Wang Jian-hu, Mei Li et al. (7 authors)
PLoS ONE
Open Access
Published: Jan 2024
Same day as retraction
Qishen Yiqi Dripping Pill Protects Diabetic Nephropathy by Inhibiting the PI3K-AKT Signaling Pathways in Rats
Shaohua Li, Guangbiao Xu
Evidence-based Complementary and Alternative Medicine
Open Access
Published: Jun 2022
4 citations
4 citations
585 days before retraction
Research Progress of Chinese Herbal Medicine Intervention in Renal Interstitial Fibrosis
Xiao‐Yuan Liu, Xu-Bin Zhang, Ya-Feng Zhao et al. (5 authors)
Frontiers in Pharmacology
Open Access
Published: Jun 2022
21 citations
21 citations
589 days before retraction
Promoting Plant-Based Therapies for Chronic Kidney Disease
Muhammad Ali Khan, Andrew J. Kassianos, Wendy E. Hoy et al. (6 authors)
Journal of Evidence-Based Integrative Medicine
Open Access
Published: Jan 2022
39 citations
39 citations
752 days before retraction
QiShenYiQi ameliorates salt-induced hypertensive nephropathy by balancing ADRA1D and SIK1 expression in Dahl salt-sensitive rats
Hongxia Du, Guangxu Xiao, Zhifeng Xue et al. (12 authors)
Biomedicine & Pharmacotherapy
Open Access
Published: Jul 2021
17 citations
17 citations
915 days before retraction
TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases
Philip Chiu‐Tsun Tang, Alex Chan, Cai-Bin Zhang et al. (9 authors)
Frontiers in Medicine
Open Access
Published: Feb 2021
42 citations
42 citations
1062 days before retraction
Qishen Yiqi Dripping Pill Protects Against Diabetic Nephropathy by Inhibiting the Wnt/β-Catenin and Transforming Growth Factor-β/Smad Signaling Pathways in Rats
Qian Zhang, Xinhua Xiao, Jia Zheng et al. (8 authors)
Frontiers in Physiology
Open Access
Published: Feb 2021
10 citations
10 citations
1068 days before retraction
QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion
Li Peng, Chong-Shan Lv, Yun Zhao et al. (10 authors)
Oncotarget
Open Access
Published: Jul 2017
8 citations
8 citations
2391 days before retraction
The protective effects of Zhen-Wu-Tang against cisplatin-induced acute kidney injury in rats
Qi Liu, HU Shou-yu, Yi He et al. (7 authors)
PLoS ONE
Open Access
Published: Jun 2017
30 citations
30 citations
2422 days before retraction
Quick Stats
Total Citations:
10
Years Since Retraction:
1.8 year
Open Access:
Yes
Last Checked:
Jul 24, 2025